Analyst Reco. Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
10.98 ^USD	-6.67%		-12.40%	-27.49%

Apr. 11	Zentalis Pharmaceuticals, Inc. Announces Executive Changes	CI
Apr. 11	Zentalis Pharmaceuticals, Inc. Announces CFO Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating	Feb. 28	MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	Jan. 23	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating	Nov. 28	MT
Wedbush Downgrades Zentalis Pharmaceuticals to Neutral From Outperform After Announced Updates to Azenosertib Strategy in Platinumsensitive Ovarian Cancer; Cuts PT to $12 From $38	Nov. 08	MT
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating	Nov. 07	MT
HC Wainwright Lowers Price Target on Zentalis Pharmaceuticals to $46 From $55, Maintains Buy Rating	Nov. 07	MT
Morgan Stanley Adjusts Price Target on Zentalis Pharmaceuticals to $38 From $55, Maintains Overweight Rating	Nov. 07	MT
Wells Fargo Adjusts Price Target on Zentalis Pharmaceuticals to $50 From $51, Maintains Overweight Rating	23-08-10	MT
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $50 From $45, Maintains Buy Rating	23-06-07	MT
Wedbush Raises Zentalis Pharmaceuticals' Price Target to $38 From $31, Says Topline Azeno Combo Data Impresses; Keeps Outperform Rating	23-05-26	MT
Jefferies Adjusts Price Target on Zentalis Pharmaceuticals to $70 From $120, Maintains Buy Rating	23-05-19	MT
Wedbush Trims Zentalis Pharmaceuticals' Price Target to $31 From $33, Adjusts Launch Timing Assumptions; Keeps Outperform Rating	23-05-11	MT
Wedbush Lifts Zentalis Pharmaceuticals' PT to $33 From $32, Sees Number of Compelling Value Opportunities Ahead; Keeps Outperform Rating	23-03-02	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $52 From $91, Maintains Buy Rating	22-11-21	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $52 From $91, Maintains Buy Rating	22-11-18	MT
Wedbush Lowers Price Target on Zentalis Pharmaceuticals to $32 From $51, Keeps Outperform Rating	22-11-14	MT
SVB Securities Trims Price Target on Zentalis Pharmaceuticals to $27 From $42, Affirms Outperform Rating	22-11-11	MT
Morgan Stanley Cuts Price Target on Zentalis Pharmaceuticals to $55 From $60, Keeps Overweight Rating	22-11-11	MT
Guggenheim Lowers Price Target on Zentalis Pharmaceuticals to $28 From $55, Maintains Buy Rating	22-11-11	MT
Oppenheimer Adjusts Zentalis Pharmaceuticals Price Target to $50 From $80, Maintains Outperform Rating	22-11-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Analyst Reco.

Filters